PreciseDx to Attend the 2024 Annual National Comprehensive Cancer Network Conference

NEW YORK, April 3, 2024 –  PreciseDx®, a leading innovator in oncology diagnostics leveraging Artificial Intelligence (AI) for revolutionary, morphology-driven disease analysis, today

announced their attendance at the Annual National Comprehensive Cancer Network (NCCN) Conference in Orlando, FL.

Ted Diehl, Vice President of Commercial Development, and Rebecca DeAngel, Senior Director of Strategic Partnerships, will be available at booth #704 for an in-depth conversation on the latest advancements at PreciseDx. Specifically, they can discuss how pioneering solutions, such as PreciseBreast™, are reshaping the landscape of oncology innovation.

WHO: PreciseDx

WHAT: Join PreciseDx at the Annual NCCN conference to discuss educational topics that focus on updates to NCCN Guidelines® across many cancer types—plus screening, prevention, supportive care, data collection and utilization, care team collaboration, and much more!

WHEN: April 5-7, 2024

WHERE: Orlando World Center Marriott, Orlando, FL; booth #704

MEDIA: PreciseDx is available for in-person briefings by request via email to precisedx@0to5.com.

About PreciseDx® 

PreciseDx® is innovating oncology diagnostics, leveraging Artificial Intelligence (AI) for revolutionary, morphology-driven disease analysis. Combining AI with our patented Morphology Feature Array® (MFA), PreciseDx provides access to unmatched disease insights and accurate, actionable intelligence for more comprehensive decision-making throughout the cancer care continuum. To learn more about PreciseDx, visit https://precisedx.ai

About PreciseBreast™

PreciseBreast™ is an early-stage invasive breast cancer risk assessment, independent of HER2, hormone, and node status. The AI-powered test utilizes standard H&E pathology slide images. Leveraging millions of data points, PreciseBreast™ analyzes, correlates, and quantifies those critical features that predict breast cancer recurrence and delivers a Risk of Recurrence Score. The test meets the rigorous Clinical Laboratory Improvement Amendments (CLIA) standards and has passed the Clinical Laboratory Evaluation Program (CLEP) Assay Validation Review by the New York State Department of Health (NYSDOH). PDxBR will be available worldwide under the brand name of PreciseBreast™. For more information, please contact precisebreast@precisedx.ai.